Dermata Therapeutics (DRMA) Income from Continuing Operations (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Income from Continuing Operations of 1847706.0 for Q1 2026, up 38.48% year-over-year from 1334244.12 in Q1 2025, and up 0.76% quarter-over-quarter from 1861888.0 in Q4 2025.
Dermata Therapeutics (DRMA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 1847706.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 38.48% year-over-year to 1847706.0; the TTM figure through Mar 2026 stood at 7102676.0 (up 57.86% YoY), while the FY2025 annual figure was 8258557.0, up 59.32% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1847706.0, up from 1861888.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1691989.0 in Q3 2025, with the low at 4973156.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 2262973.0 (2023), against an average of 2692377.35.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 189.27% in 2024, then soared 65.98% in 2025.
- Dermata Therapeutics' Income from Continuing Operations stood at 1711689.0 in 2022, then sank by 32.21% to 2262973.0 in 2023, then sank by 96.69% to 4450938.0 in 2024, then jumped by 58.17% to 1861888.0 in 2025, then gained by 0.76% to 1847706.0 in 2026.
- Business Quant data shows DRMA's Income from Continuing Operations at 1847706.0 in Q1 2026, 1861888.0 in Q4 2025, and 1691989.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Dermata Therapeutics | 5.33 Mn | 5.33 Mn | - | -1.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.85 Mn |
| Dec 31, 2025 | -1.86 Mn |
| Sep 30, 2025 | -1.69 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Mar 31, 2025 | -3.00 Mn |
| Dec 31, 2024 | -4.45 Mn |
| Sep 30, 2024 | -4.97 Mn |
| Jun 30, 2024 | -4.43 Mn |
| Mar 31, 2024 | -4.03 Mn |
| Dec 31, 2023 | -2.26 Mn |
| Sep 30, 2023 | -1.72 Mn |
| Jun 30, 2023 | -1.70 Mn |
| Mar 31, 2023 | -2.24 Mn |
| Dec 31, 2022 | -1.71 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Jun 30, 2022 | -2.73 Mn |
| Mar 31, 2022 | -2.99 Mn |
| Dec 31, 2021 | -2.55 Mn |
| Sep 30, 2021 | -4.28 Mn |
| Jun 30, 2021 | -1.33 Mn |